RedHill Biopharma (RDHL) Competitors $6.70 +0.30 (+4.69%) (As of 11:45 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends RDHL vs. MEIP, LEXX, CLNN, ESLA, ICCC, PASG, ACST, PMN, LIAN, and LTRNShould you be buying RedHill Biopharma stock or one of its competitors? The main competitors of RedHill Biopharma include MEI Pharma (MEIP), Lexaria Bioscience (LEXX), Clene (CLNN), Estrella Immunopharma (ESLA), ImmuCell (ICCC), Passage Bio (PASG), Acasti Pharma (ACST), ProMIS Neurosciences (PMN), LianBio (LIAN), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. RedHill Biopharma vs. MEI Pharma Lexaria Bioscience Clene Estrella Immunopharma ImmuCell Passage Bio Acasti Pharma ProMIS Neurosciences LianBio Lantern Pharma RedHill Biopharma (NASDAQ:RDHL) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking. Which has more risk & volatility, RDHL or MEIP? RedHill Biopharma has a beta of 3.68, indicating that its share price is 268% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Do insiders & institutionals have more ownership in RDHL or MEIP? 7.2% of RedHill Biopharma shares are owned by institutional investors. Comparatively, 52.4% of MEI Pharma shares are owned by institutional investors. 6.8% of RedHill Biopharma shares are owned by insiders. Comparatively, 3.9% of MEI Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is RDHL or MEIP more profitable? RedHill Biopharma's return on equity of 0.00% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets RedHill BiopharmaN/A N/A N/A MEI Pharma N/A -84.80%-65.24% Do analysts rate RDHL or MEIP? MEI Pharma has a consensus price target of $7.00, suggesting a potential upside of 152.71%. Given MEI Pharma's stronger consensus rating and higher possible upside, analysts plainly believe MEI Pharma is more favorable than RedHill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RedHill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MEI Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor RDHL or MEIP? RedHill Biopharma received 28 more outperform votes than MEI Pharma when rated by MarketBeat users. Likewise, 67.56% of users gave RedHill Biopharma an outperform vote while only 61.96% of users gave MEI Pharma an outperform vote. CompanyUnderperformOutperformRedHill BiopharmaOutperform Votes42767.56% Underperform Votes20532.44% MEI PharmaOutperform Votes39961.96% Underperform Votes24538.04% Does the media favor RDHL or MEIP? In the previous week, RedHill Biopharma and RedHill Biopharma both had 2 articles in the media. RedHill Biopharma's average media sentiment score of 0.42 beat MEI Pharma's score of 0.34 indicating that RedHill Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RedHill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MEI Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, RDHL or MEIP? RedHill Biopharma has higher earnings, but lower revenue than MEI Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedHill Biopharma$6.53M1.31$23.92MN/AN/AMEI Pharma$65.30M0.28$17.78M-$6.99-0.40 SummaryRedHill Biopharma beats MEI Pharma on 9 of the 13 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get RedHill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedHill BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.58M$6.49B$5.09B$8.79BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.3293.0914.02Price / Sales1.31370.921,220.6787.41Price / Cash0.0152.5939.4936.27Price / Book0.1710.236.936.33Net Income$23.92M$153.22M$118.83M$225.71M7 Day Performance-4.15%-1.99%-1.74%-0.58%1 Month Performance-22.27%-7.51%-3.60%1.49%1 Year Performance-96.64%31.02%31.91%27.23% RedHill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedHill Biopharma0.9841 of 5 stars$6.70+4.7%N/A-96.9%$8.58M$6.53M0.00210News CoverageMEIPMEI Pharma4.1926 of 5 stars$2.77-1.1%$7.00+152.7%-50.5%$18.45M$65.30M-0.40100LEXXLexaria Bioscience1.867 of 5 stars$2.15-2.3%$11.00+411.6%+78.9%$34.01M$230,000.000.007News CoverageGap DownCLNNClene3.1607 of 5 stars$4.02-1.7%$71.33+1,674.5%-56.6%$33.61M$650,000.000.00100Analyst RevisionESLAEstrella Immunopharma0.6303 of 5 stars$0.89-3.3%N/A-33.5%$32.20MN/A-3.54N/AGap DownICCCImmuCell0.5144 of 5 stars$3.59-0.3%N/A-22.1%$31.99M$17.47M-7.2075PASGPassage Bio2.9606 of 5 stars$0.52+0.3%$9.00+1,647.6%-19.0%$31.81MN/A0.00130ACSTAcasti Pharma2.3584 of 5 stars$3.37-0.9%$10.00+196.7%+59.0%$31.68MN/A-2.3432PMNProMIS Neurosciences1.1238 of 5 stars$0.96-3.5%N/A-30.8%$31.45M$10,000.000.006LIANLianBio1.1178 of 5 stars$0.29flat$3.50+1,115.5%-93.1%$31.12MN/A-0.35110LTRNLantern Pharma1.0942 of 5 stars$2.87-2.4%N/A-27.0%$30.94MN/A0.0020Positive News Related Companies and Tools Related Companies MEI Pharma Competitors Lexaria Bioscience Competitors Clene Competitors Estrella Immunopharma Competitors ImmuCell Competitors Passage Bio Competitors Acasti Pharma Competitors ProMIS Neurosciences Competitors LianBio Competitors Lantern Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RDHL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share RedHill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
